Posted by Michael Wonder on 30 Oct 2020
NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
30 October 2020 - All eligibility criteria must be met for liraglutide to be offered.
NICE has today recommended a new treatment option for those adults managing obesity and non-diabetic hyperglycaemia alongside a reduced-calorie diet and increased physical activity.
Liraglutide (Saxenda; Novo Nordisk) will be offered to adults with non-diabetic hyperglycaemia who have a body mass index of at least 35 kg per m2 and have a high risk of cardiovascular disease because of risk factors such as high blood pressure or high cholesterol levels.
